Related Experiment Video

Updated: Jun 25, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer

Charlotte Dessaux1, Laetitia Ganier1,2, Louis Guiraud1

  • 1Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Equipe labellisée Ligue 'Cell polarity, Cell signaling and Cancer', Marseille, France.

Oncogene
|May 21, 2024
PubMed

Insights

Inactive protein kinases, like PTK7 (pseudokinase receptor tyrosine kinase 7), are key cancer targets. New therapies targeting these pseudokinases show promise in preclinical and clinical cancer studies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Protein kinases are crucial drug targets in cancer therapy, with many drugs developed against active kinases.
  • Catalytically inactive protein kinases, or pseudokinases, represent 10% of the human kinome and are implicated in cancer.
  • PTK7 (pseudokinase receptor tyrosine kinase 7) is a pseudokinase overexpressed in various cancers, linked to poor prognosis and treatment resistance.

Purpose of the Study:

  • To review the role of PTK7 in cancer progression.
  • To summarize current preclinical and clinical targeting strategies for PTK7 and other pseudokinases.

Main Methods:

  • Literature review of recent data on PTK7 function in cancer.
  • Analysis of preclinical and clinical studies on PTK7-targeting therapies.

Main Results:

  • PTK7, despite lacking catalytic activity, drives cancer progression through signaling pathways, including heterodimerization with active RTKs.
  • Targeting strategies such as antibody-drug conjugates, aptamers, and CAR-T cell therapies show promising results against PTK7.
  • PTK7 is a validated target for therapeutic intervention in various solid tumors and hematological malignancies.

Conclusions:

  • PTK7 is a significant driver of cancer progression and a viable therapeutic target.
  • Emerging strategies targeting PTK7 and other pseudokinases offer new hope for cancer patients.
  • Further research into pseudokinase biology and targeted therapies is warranted.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K